Vascular Affection in Behcet Disease

Serum Elafin :A Biomarker in Behcet Disease and Its Relation to Vascular Involvement and Disease Activity

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06280430

Enrollment

Registered

2024-02-28

Start date

2024-03-01

Completion date

2025-04-01

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Behcet Disease and Vascular Involvement

Brief summary

To measure the level of serum elafin in patients with behcet disease and to assess the correlation between serum elafin and vascular affection and their relation with disease activity

Detailed description

Behcet disease is a chronic multi systemic inflammatory disease characterized by recurrent oral and genital ulcers and multiple systemic affection . Elafin is a serine protease inhibitor produced mainly by epithelial cells . previous studies documented the role of serum elafin in pathogenesis of behcet disease.vascular complications may be one if the earliest manifestation leading to the diagnosis of behcet disease.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 45 Years

Inclusion criteria

* patients diagnosed as behcet disease Age (20-45)

Exclusion criteria

* age \<20 and \>45 Other autoimmune diseases Risk factors (ischemic heart disease, diabetes) Chronic conditions (malignancy, chronic kidney disease)

Design outcomes

Primary

Measure	Time frame	Description
To measure the level of serum elafin in behcet patients and compare it with control group	Within 1year	Measure the level of serum elafin in behcet and its relation to disease activity and vascular involvement

Outcome results